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Preamble 
It is becoming apparent that despite a strong national 
commitment to excellence in health care, resources and 
personnel are finite. It is therefore appropriate that the 
medical profession examine the impact of developing tech- 
nology and new therapeutic modalities on the practice of 
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cardiology. Such analysis, carefully conducted, could poten- 
tially impact he cost of medical care without diminishing 
the effectiveness of that care. 
To this end, the American College of Cardiology and the 
American Heart Association in 1980 established a Task 
Force on the Assessment of Diagnostic and Therapeutic 
Cardiovascular Procedures (now the ACC/AHA Task 
Force on Practice Guidelines) with the following charge: 
The task force of the American College of Cardiology 
and the American Heart Association shall develop guide- 
lines relative to the role of new therapeutic approaches 
and specific noninvasive and invasive procedures in the 
diagnosis and management of cardiovascular disease. 
The task force shall address, when appropriate, the 
contribution, uniqueness, ensitivity, specificity, indications, 
contraindications a d cost-effectiveness of uch diagnostic 
procedures and therapeutic modalities. 
The task force shall emphasize the role and value of the 
developed guidelines a  an educational resource. 
The task force shall include a chair and six members, 
three representatives from the American Heart Association 
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Executive Summary 
ACC/AHA guidelines for clinical intracardiac electro- 
physiologic studies were first published in 1989. Since then 
significant changes have occurred, and this report is an 
update of the initial publication. It is divided into 12 
sections on the value of electrophysiological studies for 
diagnosis and assessment of therapy for bradyarrhyth- 
mias and tachyarrhythmias, with additional sections on 
the use of electrophysiological studies in patients with 
implantable electrical devices, indications for catheter ab- 
lation, and special considerations for pediatric patients. 
Indications for procedures are listed as Class I, Class II, and 
Class IlL 
Bradyarrhythraias 
The use of electrophysiological studies in patients with 
known or suspected bradyarrhythmias has been divided 
into sections on evaluation of patients with sinus nede 
dysfunction, atrioventricular (AV) block, and intraventric- 
ularconduction delay. For most of these patients, electrophys- 
iological studies are viewed as supplements to the analysis 
of standard electrocardiographic (ECG) recordings, which, 
in most patients, are adequate for diagnosis and clinical 
decisions. Electrophysiological studies provide useful infor- 
mation when ECG data are nondiagnostic or unobtainable. 
Possible roles for electrophysiological procedures in pa- 
tients before pacemaker implantation are also discussed in 
the section on implantable devices. 
Tachyarrhythmias 
The role of electrophysiological studies in patients with 
known or suspected tachyarrhythmias is covered in sections 
on diagnostic aad prognostic use in patients with narrow 
and wide complex tachycardias, long QT intervals, Wolff- 
Parkinson-White syndrome, and syncope of unknown 
cause. There is also a section on use of electrophysiologieal 
studies for evaluation of antiarrhythmic drug therapy. In 
general, electrophysiological d ta are considered the gold 
standard for diagnosis of most tachyarrhythmias, and their 
use is recommended whenever ECG diagnosis of an ar- 
rhythmia of clinical significance is uncertain. The value and, 
importantly, the limitations of electrophysiologieal studies 
in assessing prognosis and therapy are also discussed. 
Electrophysiological studies are considered intrinsic in the 
prescription and evaluation of implantable cardioverter- 
defibrillators for therapy of ventricular tachyarrhythmias. 
The advent of radiofrequency atheter ablation has ex- 
panded the use of electrophysiological procedures to in- 
elude therapy. These guidelines now have sections on the 
value of catheter ablation in patients with paroxysmal 
supraventricnlar t chycardia, preexcitation syndromes, ven- 
tricular tachycardia, nd atrial tachyarrhythmias such as 
atrial tachycardia, trial flutter, and atrial fibrillation. The 
guidelines state that catheter ablation is one of the primary 
treatment options for most forms of paroxysmal supraven- 
tricular tachycardias nd preexcitation syndromes, mono- 
morphic ventricular tachycardia nd structurally normal 
hearts. Use of catheter ablation is justified by the high 
success and low complication rates described in the litera- 
ture. For other tachyarrhythmias, the guidelines recom- 
mend only selective use of catheter ablation because of 
limited data about efficacy during long-term follow-up. 
However, the rapid expansion of knowledge in these areas 
is recognized. Catheter procedures to ablate or modify 
atrioventricular conduction are recognized as effective in 
controlling veutricular rates in patients with atrial tachy- 
arrhythmias. In the future, ablation may be used to elimi- 
nate atrial fibriUation. 
I. Introduction 
During the past 25 years, cardiac electrophysiological 
studies have become widely used clinical tools, often indis- 
pensable in evaluating patients with specific ardiac arrhyth- 
mias. Because such studies carry a relatively small but finite 
risk of major as well as minor complications, routinely 
involve the purposeful induction of serious arrhythmias, 
and consume healthcare sources, it is important that their 
clinical usefulness for diagnosis and therapy of cardiac 
arrhythmias be carefully considered. These guidelines pres- 
ent current opinion regarding clinical application of inva- 
give cardiac electrophysiological studies and update arlier 
publications on this subject. I-3 The American College of 
Cardiology, the American Heart Association, and the 
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recognize that the ultimate judgment regarding the appro- 
priateness of a specific procedure isthe responsibility of the 
physician caring for the patient. Therefore, these guidelines 
should not be considered all inclusive or exclusive of other 
methods that may be available for the care of the individual 
patient. Moreover, these guidelines address in only a 
limited way the cost-benefit and risk-benefit outcomes of 
these procedures. Finally, it is important to emphasize that 
this document, like the one before it, -~ will require periodic 
updating as the indications for electrophysiological studies 
continue to evolve as a result of increasing knowledge and 
technological dvances. 
It is assumed, for the purposes of this document, hat the 
electrophysiological studies are performed by appropriately 
trained and qualified personnel in adequately equipped 
laboratories, and that complete lectrophysiological stud- 
ies, indicated by the patient's clinical state and specific 
arrhythmia, re performed. In general, such studies include 
intravenous or intra-arterial placement, or both, of one or 
more electrode catheters at one or more sites in the atria, 
ventricles, or coronary sinus (occasionally in the pulmonary 
artery or aorta) or esophagus to record or stimulate at 
various rates and cadences. Such studies are performed to 
evaluate lectrophysiological properties such as automatic- 
ity, conduction, and refractoriness; initiate and terminate 
taehycardias; map activation sequences; evaluate patients 
for various forms of therapy; and judge response to therapy. 
Studies are modified according to the patient, the problem 
being investigated, and the site of the study, ie, bedside, 
operating room, or electrophysiology laboratory. Increas- 
ingly, in the course of these studies, therapeutic nterven- 
tions such as catheter ablation procedures are being 
performed. 
The indications for electrophysiological studies have 
been divided into three classes: 
Class I 
Conditions for which there is general agreement that the 
electrophysiological study provides information that is use- 
ful and important for patient reatment. Experts agree that 
patients with these conditions are likely to benefit from 
eleetrophysiological studies. 
Class II 
Conditions for which electrophysiological studies are 
frequently performed, but there is less certainty about the 
usefulness of the information that is obtained. Experts are 
divided in their opinion as to whether patients with these 
conditions are likely to benefit from electrophysiologicai 
study. 
Class III 
Conditions for which there is general agreement that 
electrophysiological studies do not provide useful informa- 
tion. Experts agree that electrophysiological studies are not 
warranted in patients with these conditions. This classifica- 
tion is assigned to patients with a variety of arrhythmias nd 
clinical syndromes resulting from cardiac electrical abnor- 
malities. Because use of electrophysioiogical studies in 
children on occasion differs from that in adults, it is 
discussed in another section. 
II. Role of Eiectrophysiologicai Study in 
Evaluating Sinus Node Function 
Electrocardiographic manifestations of sinus node dys- 
function vaay include resting sinus bradycardia, inappropri- 
ate chronotropic responses to exercise or stress, sinoatrial 
exit block, or sinus arrest. Common manifestations include 
syncope, near syncope, transient lightheadedness, or severe 
fatigue. These arrhythmias re commonly caused by one or 
more of the following: intrinsic disease within the sinus 
node (eg, idiopathic degeneration, fibrosis, ischemia, or 
surgical trauma), abnormalities in autonomic nervous ys- 
tem function, and drug effects. Clinical evaluation of sus. 
pected sinus node dysfunction is often ditficult because 
symptomatic abnormalities may be transient and healthy, 
asymptomatic persons can exhibit considerable variability 
in sinus rates. 
Several invasive tests of sinus node function have been 
proposed. Sinus node recovery time (SNRT) is used to 
evaluate the effects of overdrive suppression on sinus node 
automaticity. 4 This is often corrected for the underlying 
b,~eline sinus cycle length (SCL) and expressed as cor- 
rected sinus node recovery time (CSNRT=SNRT-SCL). 
Sinoatrial conduction can be estimated indirectly either by 
introducing atrial extrastimuli during sinus rhythm 5,~ or by 
atrial pacing. 7 Catheter ecordings of sinus node electro- 
grams have been reported, and such direct measurements 
of conduction times eem to correlate well with the indirect 
measures described above. ~,'~ 
Sinus node recovery times and sinoatrial conduction 
times are frequently abnormal in symptomatic patients with 
intrinsic sinus node disease but will usually be normal in 
patients with sinus bradyarrhythmias c used by intermittent 
factors uch as autonomic nervous ystem influences. I~.1~ A
full evaluation of sinus node f,mction frequently requires 
continuous or intermittent anlbulatory ECG recordings, 
exercise testing to assess ehronotropic competence, tilt- 
table testing, or autonomic manipulations as well as inva- 
sire electrophysiological d ta. 12 In addition, patients with 
sinus node dysfunction may also be subject to other arrhyth- 
mias that may be investigated during an electrophysiologi- 
cal study. 
Recommendations forElectrophysiologicai Studies 
Class 1 
Symptomatic patients in whom sinus node dysfunction is 
suspected as the cause of symptoms but a causal relation 
between an arrhythmia nd the symptoms has not been 
established after appropriate evaluation 
Class II 
(1) Patients with documented sinus node dysfunction i
whom evaluation of atrioventricular or ventriculeatrial 
(VA) conduction or susceptibility oarrhythmias may aid in 
selection of the most appropriate pacing modality 
(2) Patients with electrocardiographically documented 
sinus bradyarrhythmias to determine if abnormalities are 
due to intrinsic disease, autonomic nervous ystem dysfunc- 
tion, or the effects of drugs so as to help select herapeutic 
options 
(3) Symptomatic patients with known sinus bradyar- 
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rhythmias to evaluate potential for other arrhythmias the 
cause of symptoms 
Class III 
(1) Symptomatic patients in whom an association be- 
tween symptoms and a documented bradyarrhythmia h s 
been established and choice of therapy would not be 
affected by results of an electrophysiological study 
(2) Asymptomatic patients with sinus bradyarrhythmias 
or sinus pauses observed only during sleep, including sleep 
apnea 
HI. Role of Electrophysiological Study in Patients 
With Acquired Atrioventricular Block 
The electrocardiographic classification of AV block in- 
eludes these categories: 
(1) First-degree AV block-- prolongation of the PR 
interval beyond 0.20 second. 
(2) Second-degree AV block--intermittent failure to 
conduct asingle P wave. Two types have been described. In 
type I second-degree AV block (Wenckebach block) there 
is progressive prolongation of the PR interval before the 
blocked P wave; in type II AV block PR intervals are 
constant before the blocked P wave. 
(3) AV block with a 2:1 conduction ratio--not classified 
as either type I or type II but as 2:1 AV block. 
(4) Advanced or high-grade AV block--this category is
recommended by some experts to define a condition in 
which multiple consecutive P waves are blocked but com- 
plete AV block is not present. 
(5) Complete AV block--failure of all P waves to 
conduct to the ventricle, resulting in complete dissociation 
between P waves and QRS complexes. 
His bundle recordings allow delineation of three ana- 
tomic sites of AV blockl3: (1) proximal (above the His 
bundle), representing delay or block in the AV node; (2) 
intra-Hisian, representing delay or block within the His 
bundle; and (3) infra-Hisian or distal to the His bundle, 
representing block or delay distal to the His bundle recording 
site either in the distal His bundle or the bundle branches. 
There are certain correlations between ECG patterns 
and the site of block, t4 In type I second-degree AV block 
with narrow QRS complexes, the block is usually at the 
level of the AV node; less frequently it may be within the 
His bundle. In type I second-degree AV block with wide 
QRS complexes (bundle branch block), the block may be in 
the AV node or within or below the His bundle. Type 1I 
second-degree AV block is usually within or below the His 
bundle and is most often seen with bundle branch block. 
Rarely, type II AV block can be in the AV node. In 
complete AV block with an escape rhythm of narrow QRS 
complexes, the site of block may be in the AV node or 
within the His bundle. In complete AV block with an 
escape rhythm of wide QRS complexes, the site of block 
may be in the AV node or within or below the His bundle; 
usually it is below the His bundle. Clinical information 
about age, gender, underlying heart disease, and the use of 
cardiac medications may also be helpful in predicting the 
site of AV block. 
The prognosis of patients with AV block depends on the 
site of block. Chronic first-degree AV block, particularly 
AV nodal block, usually has a good prognosis. The abnor- 
mality is frequently drug related and reversible. The clinical 
course of patients with second-degree AV nodal block is 
usually benign, and prognosis depends on the presence and 
severity of underlying heart disease. 15 The prognosis of 
patients with second-degree AV block within the His 
bundle is uncertain. Such patients frequently manifest 
congestive heart failure and syncope. Untreated chronic 
second-degree AV block below the His bundle has a poor 
prognosis; patients frequently proceed to higher degrees of 
block and become symptomatic with syncope? 6 Patients 
with untreated, acquired complete AV block are often 
symptomatic regardless of the site of the block. ~7 
Recommendations for Electrophysiologicol Studies 
Class I 
(1) Symptomatic patients in whom His-Purkinje block, 
suspected as a cause of symptoms, has not been established 
(2) Patients with second- or third-degree AV block treated 
with a pacemaker who remain symptomatic and in whom 
another arrhythmia s suspected as a cause of symptoms 
Class II 
(1) Patients with second- or third-degree AV block in 
whom knowledge of the site of block or its mechanism or 
response to pharmacological or other temporary in:erven- 
tion may help direct therapy or assess prognosis 
(2) Patients with premature, concealed junctional depo- 
larizations suspected as a cause of second- or third-degree 
AV block pattern (ie, pseudo AV block). 
Class lII 
(1) Symptomatic patients in whom the symptoms and 
presence of AV block are correlated by ECG findings 
(2) Asymptomatic patients with transient AV block 
associated with sinus slowing (eg, nocturnal type I second- 
degree AV block). 
IV. Role of Electrophysiological Study in Patients 
With Chronic Intraventricular Conduction Delay 
As judged from the electrocardiogram (ECG), the intra- 
ventricular conduction system appears to be trifascicular, 
consisting of the two fascicles of the left bundle (anterior 
and posterior) and the right bundle branch. The anatomic 
basis for the trifascicular conduction system in humans is 
less clearly defined. The HV interval in patients with 
bifascicular block is a measure of the conduction time 
through the remaining functioning fascicle. Most data on 
the importance of the HV interval in predicting subsequent 
development of AV block have been derived from patients 
with bifascicular block. Patients with bifascicular block and 
a prolonged HV interval (>55 milliseconds) appear to have 
a slightly increased risk of developing complete trifascieular 
block, tS,t9 Although the prevalence of prolonged HV inter- 
val is high, the incidence of complete trifascicular block is 
low (2% to 3% annually but greater if the HV interval 
exceeds 100 milliseconds), and the rate of progression i  
the absence of an acute intervening event (drugs, electro- 
lyte abnormalities, or ischemia) is low. ts-2° Thus, the HV 
JACC Vol. 26, No. 2 ZIPES ET AL. 559 
August 1995:555-73 ACC/AHA TASK FORCE REPORT 
interval has a high sensitivity (82%) but a low specificity 
(63%) for predicting development of complete trifascicular 
block.la 
Rapid atrial pacing has been used to improve the 
specificity of electrophysiological testing in patients with 
bifascicular block. An abnormal response consists of the 
development of block distal to the His bundle with rapid 
atrial pacing during 1:1 AV nodal conduction. Functional 
block distal to the His bundle due to abrupt shortening of 
the coupling interval (such as during the long-short cycles 
of Wenckebach periods or at the onset of pacing) is not 
considered a positive response. The sensitivity of distal His 
block induced by atrial pacing is relatively low, but its 
positive predictive value for development of complete AV 
block is high. 21 
Sudden death in patients with bifascicular block may 
not be caused by the development ofcomplete trifascicu- 
lar block but rather the presence of ventricular tachy- 
arrhythmias. 22 The latter may play a significant role in 
patients with advanced heart disease and bifascicular 
block. For this reason, electrophysiological evaluation of 
patients with intraventricular conduction defects and 
unexplained symptoms hould also include study of the 
AV conduction system and evaluation of sinus node 
function and programmed atrial and ventricular stimula- 
tion to assess the propensity for development of both 
bradyarrhythmias and tachyarrhythmias in an attempt to 
induce tachyarrhythmias. 
Recommendations for Electrophysiological Studies 
Class I
Symptomatic patients in whom the cause of symptoms i  
not known 
Class II 
Asymptomatic patients with bundle branch block in 
whom pharmacological therapy that could increase conduc- 
tion delay or produce heart block is contemplated 
Class IIl 
(1) Asymptomatic patients with intraventricular con- 
duction delay 
(2) Symptomatic patients whose symptoms can be cor- 
related with or excluded by ECG events 
V. Role of Electrophysiological Study in 
Diagnosis of Patients With Narrow QRS 
Complex Tachycardias 
A narrow QRS tachycardia (QRS complex <120 milli- 
seconds) can be caused by impulse formation in the sinus 
node (sinus taehycardia),  reentry circuit in the sinus node 
or the sinus node and a part of the contiguous atrium (sinus 
node reentry), in the atrium (atrial tachycardia, atrial 
flutter, and atrial fibrillation), in the AV node-His bundle 
axis (AV junctional tachycardia), reentry involving the AV 
node and its approaches (AV nodal reentrant tachycardia), 
and reentry by the AV node-His pathway for anterograde 
AV conduction and an accessory AV pathway tbr retro- 
grade conduction (orthodromic AV reentrant tachycardia 
[AVRT]). Less commonly, impulse formation in the intra- 
ventricular specialized conduction system can lead to a 
ventricular tachycardia (VT) with a QRS complex less than 
120 milliseconds in duration (fascicular tachycardia). 23 
Frequently, careful examination of the 12-lead ECG, 
especially when a recording during carotid sinus massage or 
other vagal maneuvers i  also available, facilitates making 
the correct diagnosis. Proper identification of the site of 
origin of atrial activity, its rate, and its relation to the 
ventricular rhythm is essential. 
During a typical atrial tachycardia, trial activity pre- 
cedes each QRS complex. While the PR interval may vary 
according to the conduction capabilities of the AV node 
and the rate of the atrial tachycardia, usually the P wave is 
located in the second half of the tachycardia cycle, creating 
a PR interval shorter than the RP interval. Importantly, the 
atrial tachycardia c n continue despite the development of
AV block because activation of the ventricles is not an 
obligatory part of the tachycardia circuit. Four other nar- 
row QRS tachycardias also create an RP interval that 
usually exceeds the PR interval, including sinus node 
reentry, inappropriate sinus tachycardia, typical AV nodal 
reentry, and the permanent form of AV junctional recip- 
rocating tachycardia (PJRT). AV block with continuation 
of tachycardia c n also occur in s,_'nus node reentry, sinus 
tachycardia, nd atypical AV nodal reentry. Anterograde 
conduction over the fast conducting AV nodal pathway and 
retrograde conduction over the slowly conducting AV 
nodal pathway provide the reentrant circuit for atypical 
AV nodal reentry,* while anterograde conduction over the 
AV node and retrograde condnction over a slowly conduct- 
ing accessory pathway constitute the circuit for PJRT. Some 
patients in whom the retrograde P wave is located midway 
in the cardiac ycle have AV nodal reentry with two slowly 
conducting pathwrys, one anterogradely and the other 
retrogradely, socalled "slow-slow" AV node reentry. 
In typical AV nodal reentrant tachycardia, the atria and 
ventricles are activated simultaneously due to anterograde 
conduction over the slowly conducting pathway and retro- 
grade conduction over the fast conducting pathway. The 
retrograde P wave is obscured by the QRS complex or 
inscribed in the terminal portion of the QRS complex. 24,25 
AV block with continuation of the tachycardia can occur. 
During orthodromic AVRT, the tachycardia circuit is 
formed by anterograde conduction over the AV node and 
retrograde conduction over an accessory AV pathway; 
retrograde atrial activation follows the QRS complex, and 
the P wave is located in the ST segment. The tachycardia 
cannot continue in the presence of AV block. In both AV 
nodal reentry and orthodromic AVRT, the retrograde P 
wave occurs in the first half of the tachycardia cycle so that 
the RP interval is shorter than the PR interval. 
AV dissociation can be present during a narrow QRS 
tachycardia. When this happens, the tachycardia most 
commonly originates in the AV node-His bundle or fasci- 
cles of the ventricles. 
*We have chosen to use the term AVnodal reento' rather than AV 
junctional reentry to avoid confusion with other tachycardias, despite 
the fact that he atrial approaches to the AV node are probably 
involved in this tachycardia. 
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Recommendations f r Electrophysiological Studies 
Class I 
(1) Patients with frequent or poorly tolerated episodes 
of taehycardia that do not adequately respond to drug 
therapy and for whom information about site of origin, 
mechanism, and eleetrophysiologieal properties of the 
pathways of the tachycardia sessential for choosing appro- 
priate therapy (drugs, catheter ablation, pacing, or surgery) 
(2) Patients who prefer ablative therapy to pharmaco- 
logical treatment (see section XV) 
Class II 
Patients with frequent episodes of tachycardia requiring 
drug treatment for whom there is concern about proarrhyth- 
mia or the effects of the antiarrhythmic drug on the sinus 
node or AV conduction 
Class III 
Patients with tachycardias easily controlled by vagal 
maneuvers and/or well-tolerated drug therapy who are not 
candidates for nonpharmacological therapy 
VI. Role of Electrophysiological Study in 
Diagnosis of Patients With Wide QRS 
Complex Tachycardias 
Wide QRS complex tachycardias (>--120 milliseconds in 
adults) can be caused by supraventricular rrhythmias with 
fixed or rate-related aberrant intraventricular conduction, 
supraventricular rhythmias with anterograde preexc~ta- 
tion, and ventricular arrhythmias. Although numerous au- 
thors have proposed ECG criteria to differentiate supraven- 
tricular tachycardia with aberration from ventricular 
tachyeardia? ~-29 this distinction may remain difficult even if 
complete ECG tracings are available for analysis. Arrhyth- 
mias with anterograde preexeitation may be particularly 
ditficult to differentiate from VT based on QRS morphol- 
ogy criteria during tachycardia lone, Some arrhythmias, 
such as bundle branch reentry or atriofascicular tract 
tachycardias, have QRS patterns that are not different from 
those in the more commonly encountered forms ofsupraven- 
tricular tachycardia with aberration. Finally, some fraction 
of VTs may have QRS durations of -<120 milliseconds with 
an abnormal QRS morphology, -~() and in pediatric patients 
VT QRS duration can be less than 120 milliseconds. 
Electrophysiological studies permit accurate diagnosis of 
virtually all wide complex tachycardias, and the sequence of 
and relation between atrial and ventricular activation can 
be determined. Electrograms from structures not represent- 
ed on the surface ECG (eg, the His bundle or accessory 
pathways) can be recorded and responses to various pacing 
maneuvers can be analyzed. Because knowledge of the 
mechanism of arrhythmia is often critical for selecting 
appropriate therapy, electrophysiological studies for diag- 
nosis are frequently of significant clinical value in patients 
with wide complex tachycardias. 
Recommendations forElectrophysiological Studies 
Class I 
Patients with wide QRS complex tachycardia in whom 
correct diagnosis is unclear after analysis of available ECG 
tracings and for whom knowledge of the correct diagnosis is 
necessary for patient care 
Class 11 
None 
Class III 
Patients with VT or supraventricular tachycardia with 
aberrant conduction or preexcitation synu ~mes diagnosed 
with certainty by ECG criteria and for whom invasive 
eleetrophysiological data would not influence therapy. 
However, data obtained at baseline electrophys- 
iological study in these patients might be appropriate as a 
guide for subsequent therapy (see sections on therapy). 
VII. Role of Eiectrophysiological Study in 
Patients With Prolonged QT Intervals 
Prolongation of the QT interval and its association with 
potentially life-threatening ventricular tachyarrhythmias 
may occur chronically or intermittently as part of the 
congenital prolonged QT interval syndrome or may be 
acquired secondary to metabolic, toxic, or pathophysiolog- 
ical factors. 31 The autonomic nervous ystem and catechol- 
amines can influence xpression and manifestations of both 
congenital and acquired long QT interval syndromes. 3-"
The role of electrophysioiogical studies in diagnosis and 
evaluation of, or guiding therapy for, either congenital or 
acquired QT prolongation is limited. 3~ Electrophysiological 
studies in patients with congenital ong QT syndrome 
infiequently result in initiation of ventricular arrhyth- 
mias 32,34,3s and are of limited or no predictive value. 34 
Catecholamine infusion during electrophysiologicai study 
or continuous ECG monitoring has been proposed as a 
method of unmasking clinically subtle forms of prolonged 
QT interval syndromes in symptomatic patients:: but the 
positive and negative predictive accuracies of these meth- 
ods have not been fully defined. Electrophysiological stud- 
ies have been used for diagnostic purposes in patients who 
have unexplained syncope or symptomatic arrhythmias with 
acquired prolongation of the QT interval while receiving 
drugs with the potential for inducing torsade de pointes. 
However, the prognostic significance of drug-induced 
changes in the pattern of inducibility of ventricular arrhyth- 
mias remains uncertain?' Monophasic action potential 
recordings may provide measures of action potential dura- 
tions and identification of afterdepolarizations 3z.37,3~ but at 
present are limited by the technical difficulty of achieving 
stable and reproducible recordings from defined sites. 
Recommendations forElectrophysiological Studies 
Class I 
None 
Class II 
(I) Identification of a proarrhythmic effect of a drug in 
patients experiencing sustained VT or cardiac arrest wbi!e 
receiving the drug 
(2) Patients who have equivocal abnormalities of QT 
interval duration or TU wave configuration, with syncope 
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or symptomatic arrhythmias, in whom catecholamine ef- 
fects may unmask a distinct QT abnormality 
Class III 
(1) Patients with clinically manifest congenital QT pro- 
longation, with or without symptomatic arrhythmias 
(2) Patients with acquired prolonged QT syndrome with 
s:,mptoms closely related to an identifiable cause or 
mechanism 
VIII. Role of Eiectrophysiological 
Study in Patients With 
Wolg-Parkinson-White Syndrome 
In Wolff-Parkinson-White (WPW) syndrome, patients 
are symptomatic from tachyarrhythmias caused by an 
anomalous AV connection (accessory pathway) that causes 
ventricular preexcitation and participates in supraventricu- 
lar arrhythmias. The prevalence ofventricular preexcitation 
is thought o be 0.1% to 0.3% in the general population. 
Estimates of arrhythmia ncidence in patients with preexci- 
tation vary widely, ranging from 12% to 80% in several 
surveys.39-41 
AVRT is the most common arrhythmia n patients with 
WPW syndrome. This tachycardia s further classified as 
either orthodromic AVRT, which occurs in 70% of symp- 
tomatic patients? 2 or antidromic AVRT, which occurs in 
only 4% to 5% of patients. 43"'" During orthodromie AVRT, 
the reentrant impulse propagates from atrium to ventricle 
by way of the normal conduction system (AV node and 
His-Purkinje system) and then propagates retrogradely to
the atrium over the accessory pathway. During antidromic 
AVRT the reentrant impulse propagates from atrium to 
ventricle by conduction over the accessory pathway and 
retrogradely tothe atrium by either the normal conduction 
system (His-Purkinje system and AV node) or another 
accessory pathway. 
The prevalence of atrial fibrillation, the second most 
common arrhythmia in patients with WPW syndrome, 
ranges from 10% to 38%. 42A6,47 Atrial fibrillation can be 
complicated by a very rapid ventricular esponse (via 
conduction over the accessory pathway), which can lead to 
ventricular fibrillation. Patients with WPW syndrome and a 
history of ventricular fibrillation are more likely to have a 
history of both AVRT and atrial fibrillation, multiple 
accessory pathways, and rapid conduction over the acces- 
sory pathway during atrial fibrillation (shortest preexcited 
RR interval of <250 milliseconds during electrophysiolog- 
ical study). 48 The incidence of sudden cardiac death in 
patients with WPW syndrome has been estimated at 0.15% 
per patient year and is probably even lower in asymptom- 
atic patients with ventricular preexcitation. 4'~ 
Electrophysiological study can be used in patients with 
WPW syndrome to determine the mechanism ofthe clinical 
arrhythmia, electrophysiological properties (such as con- 
duction capability and refractory periods) of the accessory 
pathway and the normal conduction system, number and 
location of accessory pathways (which is necessary for 
catheter ablation), and response to pharmacological or
ablation therapy. 
Recommendations f~r Electrophysiological Studies 
Class I 
(1) Patients being evaluated for catheter ablation or 
surgical ablation of an accessory pathway 
(2) Patients with ventricular preexcitation who have 
survived cardiac arrest or who have unexplained syncope 
(3) Symptomatic patients in whom determination f the 
mechanism ofarrhythmia or knowledge of the electrophys- 
iological properties of the accessory pathway and normal 
conduction system would help in determining appropriate 
therapy 
Class II 
(1) Asymptomatic patients with a family history of 
sudden cardiac death or with ventricular preexcitation but 
no spontaneous arrhythmia who engage in high-risk occu- 
pations or activities and in whom knowledge of the electro- 
physiological properties of the accessory pathway or induc- 
ible tachycardia may help determine recommendations for 
further activities or therapy 
(2) Patients with ventricular preexcitation who are un- 
dergoing cardiac surgery for other reasons 
Class HI 
Asymptomatic patients with ventricular preexcit:~tion, 
except hose in Class II above. 
IX. Role of Electrophysiological Study in 
Patients With Premature Ventricular 
Complexes, Couplets, and Nonsustained 
Yentricular Tachycardia 
Frequent or repetitive ventricular ectopy and nonsus- 
tained ventricular tachycardia (three or more consecutive 
ventricular complexes that last less than 30 seconds and do 
not produce loss of consciousness) can occur in patients 
with structurally normal and abnormal hearts. In treating 
these patients th? clinician must consider both symptoms 
caused by the ventricular ectopy itself and the prognostic 
significance of these arrhythmias. 
Patients with frequent or ,'~petitive ventricular ectopy 
ma t e~perience symptoms such as palpitations, fatigue, and 
near-syncope in association with these arrhythmias. If the 
symptoms are mild or infrequent, it may be possible to 
avoid therapy. In patients in whom symptoms are poorly 
tolerated, electrophysiological study may be used to locate 
the site(s) of origin of the arrhythmia. If identified, the site 
can be treated with catheter ablation; documentation f 
recurrent ventricular complexes with a single discrete ECG 
morphology as the cause of symptoms i usually required. 
This approach as been highly successful in patients with 
VTs and structurally normal hearts2 °.5~ 
Frequent or complex ventricular ectopy has also been 
associated with an adverse prognosis in some clinical situ- 
ations. 5-~ The coexistence of other prognostic variables, 
including the presence and type of structural heart disease, 
severity of ventricular dysfunction, abnormalities on a 
signal-averaged ECG, and loss of normal heart rate vari- 
ability may also be used to assess prognosis. 5-~'57 In patients 
with coronary artery disease, clinical trials have tested the 
hypothesis that pharmacological therapy directed at sup- 
pression of ventricular ectopy reduces incidence of sudden 
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death; no benefit from such therapy has been shown. 5s,s9 
Indeed, in the Cardiac Arrhythmia Suppression Trial, sup- 
pression of ventrieular ectopy using flecainide, encainide, 
or morieizine was associated with increased mortality. 6°
A number of studies have assessed the value of pro- 
grammed ventricular stimulation for estimating risk of 
future arrhythmic and total mortality, s7,61-7° These studies 
varied widely in methods of patient selection, stimulat'ion 
protocols used, and definitions of relevant end points for 
stimulation. Data from patient groups with disorders other 
than prior myocardial infarction (MI) are too limited to 
provide clinical guidance. Among patients with prior MI, 
ability to induce a sustained monomorphie VT with pro- 
grammed stimulation is associated with a greater than 
twofold risk of arrhythmia-related d ath during follow-up. 71 
Controlled clinical trials are now under way to test the 
hypothesis that induction of VT and subsequent suppres- 
sion of induction will effectively identify patients at highest 
risk and modify that risk with therapy. 72 
Recommendations f r Electrophysiological Studies 
Class I 
None 
Class II 
(1) Patients with other isk factors for future arrhythmic 
events, such as a low ejection fraction, positive signal- 
averaged ECG, and nonsustained VT on ambulatory ECG 
recordings in whom electrophysiological studies will be 
used for further isk assessment and for guiding therapy in 
patients with induc~le VT 
(2) Patients with highly symptomatic, uniform morphol- 
ogy premature ventricular complexes, couplets, and non- 
sustained VT who are considered potential candidates for 
catheter ablation 
Class HI 
Asymptomatic or mildly symptomatic patients with pre- 
mature ventricular complexes, couplets, and nonsustained 
VT without other risk factors for sustained arrhythmias 
X. Role of Electrophysiological Study in 
Patients With Unexplained Syncope 
Syncope, near-syncope, and transient lightheadedness 
are common medical problems. Before the use of head-up 
tilt testing to identify a neurocardiogenic cause of syncope, 
the results of a large prospective study revealed that 
approximately 50% of patients had a definable cause of 
syncope: haif cardiovascular nd half noncardiovascular. 
The causes in the remaining 50% remained obscure. 73 
Based on subsequent observations u ing head-up tilt test- 
ing, it is now recognized that in many in the latter group, 
plus some in the noncardiovascular group, abnormal neu- 
rocardiac reflexes was the underlying mechanism.74 In the 
absence of manifest cardiac arrhythmias or structural car- 
diac disease, neurocardiogenic syncope now appears to be a 
common cause of unexplained syncope.75. 6 However, elec- 
trophysiological studies continue to be used to detect 
arrhythmias  a possible cause of syncope in persons at risk 
for or with manifestations of cardiac disease. 77-85 Syncope in 
the presence of cardiovascular disease heralds amuch higher 
mortality risk than syncope without structural heart disease. A
12-lead ECG is not likely to provide specific etiologic or 
prognostic nformation that is useful for guiding therapy, but it 
may yield insight into the nature of underlying structural heart 
disease, the relevance of which may be defined uring further 
diagnostic studies. 
In the presence of structural heart disease, arrhythmias 
are a primary consideration among causes of syncope. 
Long-term ambulatory ECG recordings, head-up tilt test- 
ing, or exercise testing, alone or in combination, can be 
useful, but in patients with suspected ventricular arrhyth- 
mias, these tests hould not necessarily precede or supplant 
electrophysiological studies. Syncope or near-syncope asso- 
ciated with ventricular tachyarrhythmias, rapid supraven- 
trieular tachycardias, or transient bradyarrhythmie events 
are sporadic, and thus continuous ambulatory recordings 
are often unrewarding. Electrophysiological studies can be 
used to identify the presence of a pathophysio!ogical sub- 
strate that establishes risk fer developing symptomatic 
arrhythmias. Its place in the evaluation of unexplained 
syncop~ in the individual patient depends on the relative 
probabilities of a cardiac cause, as determined by clinical 
judgment. 
During electrophysiological studies, attempts are made 
to evaluate sinus node function, AV conduction, and induc- 
ibility of supraventricular and ventdcular tachyarrhythmias. 
In patients with structural heart disease, the most common 
abnormality identified uring eleetrophysiological testing is 
VT. Less frequently, His-Purkinje block and sinus node 
dysfunction are encountered. Induction of sustained mono- 
morphie VT, paroxysmal supraventricular t chycardia, His- 
Purkinje block, and evidence of sinus node dysfunction may 
have diagnostic and prognostic value in patients with 
unexplained syncope. Induction of atrial fibrillation, atrial 
flutter, nonsustained VT, polymorphie VT, and ventricular 
fibrillation induced by aggressive protocols may be nonspe- 
citic and must be interpreted car,:fully. 
In general, among patients without structural heart 
disease who have a normal ECG, the diagnostic yield of 
electrophysiological studies is low, sl and head-up tilt testing 
may provide useful diagnostic information. ~4 In contrast, in 
patients with underlying structural heart disease, such as prior 
MI, partiealarly if the signal-averaged ECG shows late poten- 
tials, an arrhythmia s more likely to be the cause of syncope, 
and electrophysiological testing has a high priority. However, 
the po~ibSt-y that the patient with structural heart disease 
~ay also have neurocardiogenic syncope should not be 
overlooked. 
Recommendations f r Electrophysiological Studies 
Class I 
Patients with suspected structural heart disease and 
syncope that remains unexplainzd after appropriate evalu- 
ation 
Class II 
Patients with recurrent unexplained syncope without 
structural heart disease and a negative head-up tilt test 
Class HI 
Patients with a known cause of syncope for whom 
treatment will not be guided by electrophysiological testing 
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XI. Role of Electrophysiological Study in 
Survivors of Cardiac Arrest 
Patients resuscitated from cardiac arrest not associated 
with a new Q-wave MI remain at high risk for recurrent 
cardiac arrest and sudden cardiac death during long-term 
follow-up. 86"9° Although reported to be 30% at 1 year of 
follow-up and 45% at 2 years of follow-up in the 1970s, 88,89 
the current magnitude of risk is unknown. Risk of recurrent 
cardiac arrest may be declining due to the combination of 
the overall decrease in cardiovascular mortality, more 
aggressi~ therapy targeted to the pathophysiology and 
manifestations of the underlying heart diseases (eg. throm- 
bolytic and coronary artery revasculadzation strategies), 
and therapy aimed specifically at cardiac arrhythmias. Cur- 
rent natural history figures are unavailable because of the 
failure to control for these variables, but these patients are 
still considered to be at excess risk for recurrent cardiac 
arrest. 91 
In the absence of antiarrhythmic drug therapy, ventric- 
ular tachyarrhythmias can be initiated during electro- 
physiological studies in 70% to 80% of patients resuscitated 
from cardiac arrest. Sustained monomorphic VT is induc- 
ible in 36% to 51% of the patients, with various proportions 
of ventricular fibrillation, monomorphic orpolymorphic VT 
degenerating to fibrillation, and nonsustained VT distrib- 
uted among the remainder. 92-97 Among the subgroup of 
cardiac arrest survivors in whom sustained monomorphic 
VT is identified as the electrical mechanism initiating 
cardiac arrest, the percentage of patients with inducible 
monomorphic VT is considerably higher. The ability to 
prevent induction of a previously inducible sustained ven- 
tricular tachyarrhythmia, as a result of pharmacological or 
surgical intervention, is associated with a more favorable 
outcome during follow-up than is failure to identify a 
successful therapeutic end point? ~-~°2 Stratification by ejec- 
tion fraction is a major modifier of outcome after successful 
suppression of inducibility. 97 
Identification of a drug that suppresses inducible VT or 
fibrillation has been reported in 26% to 80% of survivors of 
cardiac arrest, 92-97 with most studies clustering toward the 
lower rather than higher percentages. Survivors of cardiac 
arrest whose arrhythmias remain inducible at the time of 
discharge from the hospital are at more than twice the risk 
of recurrent cardiac arrest compared with those with ven- 
tricular tachyarrhythmias that are rendered noninducible. 97 
The value of preoperative and postoperative studies in 
cardiac arrest survivors who undergo surgical therapy de- 
pends on the nature of the arrhythmias. Among patients 
with ventricular fibrillation associated with a transient 
ischemic mechanism, electrophysiological studies are of 
limited usefulness; however, in patients who have inducible 
monomorphic VT before surgery and who undergo map- 
guided antiarrhythmic surgical procedures, postoperative 
studies are useful for predicting freedom from ventricular 
tachyarrhythmias during follow-up. 1°3,1°4 
The significance of failure to induce ventricular tachyar- 
rhythmias during baseline electrophysiological studies in 
the absence of antiarrhythmic drugs in survivors of cardiac 
arrest has been a source of debate in the past. However, it 
is now generally accepted that patients with depressed left 
ventricular function and no oLvious reversible cause of 
arrhythmias (eg, ischemia) remain at risk for recurrent 
cardiac arrest, despite failure ~:o induce ventricular tachy- 
arrhythmias at baselineY In contrast, patients with a 
documented ischemic mechanism for cardiac arrest who 
have a normal or near-normal ejection fraction and do 
not have inducible ventricular tachyarrhythmias during 
electrophysiological testing remain at low risk after treatment 
of the underlying ischemia. Among patients who are candi- 
dates for implantable cardioverter-defibriUator devices, pre- 
implant studies are useful for determining the most appropri- 
ate type of device for implantation. The nature of induced 
arrhythmias, in terms of electrical and hemodynamic stability 
and ability to terminat, the arrhythmia by pacing, will guide 
the choice of device therapy. ~°5 
Among patients who have unexplained cardiac arrest in 
the absence of  structural heart disease, electrophysiological 
studies are u~'ed to identify a therapeutic target, but the 
yield of such studies is considerably lower than in those with 
structural heart disease. ~°6 
Recommendations for Electrophysiological Studies 
Class I 
(1) Patients urviving cardiac arrest without evidence of 
an acute Q-wave MI 
(2) Patients surviving cardiac arrest occurring more 
than 48 hours after the acute phase of MI in the absence of 
a recurrent ischemic event 
Class II 
(1) Patients surviving cardiac arrest caused by 
bradyarrhythmia 
(2) Patients urviving cardiac arrest hought to be asso- 
ciated with a congenital repolarization abnormality (long 
QT syndrome) in whom the results of noninvasive diagnos- 
tic testing are equivocal 
Class IH 
(1) Patients surviving a cardiac arrest that occurred 
during the acute phase (<48 hours) of MI 
(2) Patients with cardiac arrest resulting from clearly 
definable specific auses uch as reversible ischemia, severe 
valvular aortic stcnosis, or noninvasively defined congenital 
or acquired long QT syndrome 
XII. Role of Electrophysiological Study in 
Patients With Unexplained Palpitations 
Long-term ambulatory recording is the most useful 
procedure for documenting cardiac rhythm associated with 
palpitations. The recording can be a continuous 24-hour 
recording if palpitations occur daily, or a loop or event 
recording if infrequent, t°7 Electrophysiological studies are 
used if recording attempts fail to provide an answer. The 
sensitivity of electrophysiological studies is low in patients 
with unexplained palpitations. 
Recommendations for Electrophysidogical Studies 
Class i 
(1) Patients with palpitations who have a pulse rate 
documented by medical personnel as inappropriately rapid 
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and in whom ECG recordings fail to document the cause of 
the palpitations 
(2) Patients with palpitations preceding a syncopal epi- 
sode 
Class II 
Patients with clinically significant palpitations, uspected 
to be of cardiac origin, in whom symptoms are sporadic and 
cannot be documented. Studies are performed to deter- 
mine the mechanisms of arrhythmias, direct or provide 
therapy, or assess prognosis. 
Class IH 
Patients with palpitations documented to be due to 
extracardiac causes (eg, hyperthyroidism) 
XIII. Role of Eiectrophysiologicai Study in 
Guiding Drug Therapy 
Electrophysiological studies allow serial assessment of 
drug-induced changes in conduction and refractoriness in 
cardiac tissues and in properties of arrhythmias, including 
inducibility, and, if inducible, rate, morphology, and hemo- 
dynamic onsequences. After a baseline study (preferably 
when the patient is off medication) during which an arrhyth- 
mia is induced, a drug is administered, and electrical 
stimulation is repeated. It has been proposed that drug- 
induced suppression of ability to reinduce the arrhythmia 
will predict freedom from recurrent arrhythmias. Con- 
versely, if the arrhythmia remains inducil:le, the probability 
of arrhythmia recurrence is higher than if suppression had 
been achieved. This approach as been used primarily in 
patients with sustained VT and in survivors of cardiac 
arrest, but similar studies in patients with supraventricul~r 
arrhythmias are also possible. 
Ventrieular Arrhythmias 
Sustained VT can be initiated with programmed stimu- 
lation in over 90% of patients with prior MI and a history 
of sustained monomorphic VT. Induction rates are lower in 
patients whose clinical presentation was cardiac arrest, in 
patients with nonsustained VTs, and with other forms of 
heart disease. If a sustained arrhythmia can be initiated at 
baseline, observational studies have indicated that arrhyth- 
mia-free survival is higher among patients m whom drug- 
induced suppression of arrhythmia induction was achieved 
at a follow-up study. ~6-H~2 It is not clear whether the higher 
arrhythmia-free survival rate is due to the effects of the 
antiarrhytlamic drug or whether this response to electrophys- 
iological testing merely selects out patients at lower risk. 
Among patients in whom VT remains inducible, character- 
istics of the arrhythmia induced uring electrophysiological 
study predict features of future recurrences.HJ~.H '- When the 
tachycardia s not significantly modified by drug effect, an 
adverse risk for both recurrent tachycardias nd mortality is
predicted. However, when the tachycardia cycle length is 
prolonged by i00 milliseconds or more and the induced 
tachycardia s hemodynamically stable, mortality outcome 
is similar to risk predicted by successful drug therapy, while 
the risk of recurrent tachycardia parallels the data for drug 
failure, m~ 
Alternative approaches for guidance of antiarrhythmic 
drug therapy are available. In selected patients, empiric 
therapy with a ~-adrenergic blocker ~°~ or amiodarone ~°9 
may be useful and, in some patients, superior to therapy 
with other agents guided by serial electrophysiological 
study. Sotalol has also been shown to be superior to con- 
ventional antiarrhythmic agents in one study. ~t° Two ran- 
domized trials ~ L~ ~2 and several observational studies TM ~, 
have compared serial ambulatory monitoring and serial 
electrophysiological testing as methods for selecting antiar- 
rhythmic drug therapy. Data from these trials are discor- 
dant because of methodological limitations of the studies, 
the significant long-term toxicity of the drugs tested, and 
the relative inefficacy of most drugs when assessed by serial 
electrophysiological testing. Hence, superiority of either 
technique is still unclear, and at present both invasive and 
noninvasive methods can be considered part of the evalu- 
ation for therapy. 
Supraventricular Ar hythmias 
The effects of antiarrhythmic drugs on tissues involved in 
supraventricular arrhythmias can be assessed with electro- 
physiological studies. Factors associated with clinical suc- 
cess in patients with paroxysmal supraventricular t chycar- 
dia due to atrioventricular nodal reentry or atrioventricular 
reentry include induction of block or marked lengthening of
the refractory period in one limb of a reentrant circuit, 
suppression of the ability to initiate sustained arrhythmia, 
and reduction of maximum ventricular rates during atrial 
fibrillat!on i~: patients with preexcitation, t ~7-~ L~ Isoprotere- 
nol has reversed many of these antiarrhythmic drug effects, 
thus limiting the predictive value of these acute observa- 
tions, m~ Only limited data concerning the predictive value 
of suppression of induction of other atrial arrhythmias are 
available. 
Recommendations f r Electrophysiological Studies 
Class I 
(1) Patients with sustained VT or cardiac arrest, espe- 
cially those with prior MI 
(2) Patients with AVNRT, AV reentrant taehycardia 
using an accessory pathway, or atrial fibrillation associated 
with an accessory pathway, for whom chronic drug therapy 
is planned 
Class II 
(1) Patients with sinus node reentrant tachycardia, trial 
tachycardia, trial fibrillation, or atrial flutter without ven- 
tricular preexcitation syndrome, for whom chronic drug 
therapy is planned 
(2) Patients with arrhythmias not inducible during con- 
trol electrophysiological study for whom drug therapy is 
planned 
Class III 
(1) Patients with isolated atrial or ventricular premature 
complexes 
(2) Patients with ventricular fibrillation with a clearly 
identified reversible cause 
JACC Vol. 26, No. 2 Z1PES ET AL. 565 
August 1995:555-73 ACC/AHA TASK FORCE REPORT 
XIV. Role of Electrophysiological Study in 
Patients Who Are Candidates for or Who Have 
Implantable Electrical Devices 
The role of electrophysiological studies in determining 
the need for permanent pacing has already been discussed 
in the sections on sinus node dysfunction (section II) and 
AV block (sections III and IV). Electrophysiological stud- 
ies can also be used before pacemaker implantation to 
provide physiological data that can influence the mode, 
site(s), and programmable pacing functions to be chosen in 
the long-term pacing prescription, m-t23 Most modern per- 
manent pacemakers have sophisticated telemetry capabili- 
ties that allow noninvasive assessment of many aspects of 
pacemaker function after insertion. Additional invasive 
electrophysiological procedures arc only needed when dif- 
ferent sites of stimulation are required or the implanted 
system cannot replicate the modality of pacing to be tested. 
Implantable lectrical devices are an important hera- 
peutic option in many patients with tachyarrhythmias. 
Some arrhythmias (eg, torsade de pointes and atrial fibril- 
lation in patients with sinus node dysfunction) can arise in 
the setting of bradycardias, and standard bradycardia pac- 
ing may be helpful in preventing future episodes. 124,125 In 
selected individuals, dual-chamber pacemakers pro- 
grammed with short AV delays have been used to prevent 
some AV reentrant tachycardias, lz6 Antitachycardia p cing 
with extrastimuli or bursts can be used to terminate many 
supraventrieular and ventricular arrhythmias. However, be- 
cause antitachycardia p cing can accelerate the original 
tachycardia, utomatic antitachycardia p cing for ventricu- 
lar arrhythmias i not advisable unless automatic defibril- 
lation back-up is available. In patients with supraventricular 
arrhythmias, risks associated with the potential induction of 
atrial fibrillation must be considered before antitaehycardia 
pacing is prescribed. Electrophysiological studies per- 
formed before device implantation may be used to assess 
the potential efficacy and risks associated with antitachycar- 
dia pacing. 
Implantable cardioverter-defibrillators (ICDs) have 
been in use for more than 15 years. ~z7 There is general 
consensus that they prevent sudden arrhythmic deaths, but 
their effects on total mortality, particularly in patients with 
depressed ventricular function, are still uncertain. 128,~29 
Advances in ICD technology have been rapid, and current 
devices often include antitachycardia p cing, bradycardia 
pacing, low energy cardioversion, high energy defibrillation, 
sophisticated diagnostic functions, capability to perform 
noninvasive programmed stimulation, and transvenous or 
subcutaneous lead systems. 13°.131 
Data obtained during electrophysiological studies are 
used to guide selection of the appropriate implantable 
electric device and for programming long-term device 
settings. Electrophysiological studies are appropriate be- 
fore implantation to assess the characteristics of the ar- 
rhythmia or arrhythmias to be treated, at implantation to 
assess the efficacy of the device, and after implantation to 
confirm continued effectiveness, particularly if changes in 
the patient's status or therapy that might affect he function 
of the device have occurred. 
Recommefutations f r Electrophysiological Study 
Class I 
(1) Patients with tachyarrhythmias, before and during im- 
plantation, and final (predischarge) programming of an elec- 
trical device to confirm its ability to perform as anticipated 
(2) Patients with an implanted electrical antitachyarrhyth- 
mia device in whom changes in status or therapy may have 
influenced the continued safety and efficacy of the device 
(3) Patients who have a pacemaker to treat a bradyar- 
rhythmia, and receive acardioverter-defibrillator, to test for 
device interactions 
Class II 
Patients with previously documented indications for 
pacemaker implantation to test for the most appropriate 
long-term pacing mode and sites to optimize symptomatic 
improvement and hemodynamics 
Class HI 
Patients who are not candidates for device therapy 
XV. Indications for Catheter 
Ablation Procedures 
Catheter ablation was introduced in the early 1980s and 
has become the treatment of choice for some arrhythmias 
and an important consideration for others. More than 
10 000 ablation procedures were performed in the United 
States in 1992, with complication rates as low as 2% in some 
patient groups. 132 Catheter ablation has largely supplanted 
open-heart surgical procedures for several types of arrhyth- 
mias and is an acceptable alternative to long-term drug 
therapy. The role of catheter ablation as primary therapy 
for several arrhythmias has been described in position 
papers or technology assessments bythe American Medical 
Association, 133 the American College of Cardiology, j34 and 
the North American Society of Pacing and Electrophysiol- 
ogy. j3-~ The use of direct current shocks for ablation has 
largely been relegated to a secondary role. Other energy 
sources are being evaluated, but these guidelines relate 
primarily to the use of radiofrequency urrent for ablation. 
Radiofrequency Catheter Ablation or Modification of 
Atrioventicular Junction for Ventricular Rate Control 
of Atrial Tachyarrhythmias 
Catheter ablation of the AV junction (producing com- 
plete AV block) is well established as a means of control- 
ling ventricular response in patients with poor rate control 
who are receiving medical therapy. Recently, selective 
ablation in the region of the posteroseptal nd midseptal 
approaches to the AV node has been used to control 
ventricular esponse without producing complete AV 
block.13~ 
The efficacy of producing complete AV block by radio- 
frequency ablation of the AV junction varies from 70% to 
95% and is usuair~ 37,% or more. 132.137-14t Complication 
rates are generally less than 2%, and procedure-related 
deaths are estimated at 0.1%. 132 Late sudden death may 
follow AV junction ablation but may be less with radiofre- 
quency ablation than DC shock ablation, l~z Many patients 
undergoing ablation of the AV junction have severely 
compromised cardiac function, and it is uncertain whether 
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the late deaths are directly related to the ablative procedure 
or the underlying myocardial disease. 
Recommendations for Radiofrequency Catheter Ablation 
and Modification of Atrioventricular Junction 
Class I 
(1) Patients with symptomatic atrial tachyarrhythmias 
who have inadequately controlled ventricular rates unless 
primary ablation of the atrial taehyarrhythmia is possible 
(2) Patients with symptomatic atrial tachyarrhythmias 
such as those above but when drugs are not tolerated or the 
patient does not wish to take them, even though the 
ventricular rate can be controlled 
(3) Patients with symptomatic nonparoxysmal junc- 
tional tachycardia that is drug resistant, drugs are not 
tolerated, or the patient does not wish to take them 
(4) Patients resuscitated from sudden cardiac death due 
to atrial flutter or atrial fibrillation with a rapid ventricular 
response in the absence of an accessory pathway 
Class II 
Patients with a dual-chamber pacemaker and pacemak- 
er-mediated tachycardia that cannot be treated effectively 
by drugs or by reprogramming the pacemaker 
Class IH 
Patients with atrial tachyarrhythmias re ponsive to drug 
therapy acceptable to the patient 
Radiofrequency Catheter Ablation for Atrioventricular 
Nodal Reentrant Tachycardia 
The AV node includes "fast" pathways with atrial con- 
nections located anteriorly and "slow" pathways with atrial 
connections located posteriorly. In the most common type 
of AVNRT, the slow pathway is used for anterograde 
conduction and the fast pathway is used for retrograde 
conduction. Both pathways are needed to maintain 
AVNRT. The atrial connection of either the fast or slow 
pathway can be ablated, thereby eliminating AVNRT. Slow 
pathway ablation is preferred because of a lower incidence 
of producing AV block, a greater likelihood of maintaining 
a normal PR interval during sinus rhythm, and its efficacy in 
the atypical forms of AVNRT. The 1992 NASPE survey ~32 
included 3052 patients undergoing slow pathway ablation 
with a success rate of 96% and 255 patients undergoing 
fast pathway ablation with a success rate of 90%. Recur- 
rence of AVNRT after an initially successful procedure 
has an estimated frequency of about 5%. Overall compli- 
cations were 0.96%; no procedure-related deaths were 
reported. 
Recommendations f r Radiofrequency Catheter Ablation for 
Alrioventricular Nodal Reentrant Tachycardia 
Class I 
Patients with symptomatic sustained AVNRT that is 
drug resistant or the patient is drug intolerant or does not 
desire long4erm drug therapy 
Class II 
(1) Patients with sustained AVNRT identified during 
electrophysiological study or catheter ablation of another 
arrhythmia 
(2) The finding of dual AV nodal pathway physiology 
and atrial echoes but without AVNRT during electrophys- 
iological study in patients suspected of having AVNRT 
clinically 
Class I l l  
(1) Patients with AVNRT responsive to drug therapy 
that is well tolerated and preferred by tile patient to 
ablation 
(2) The finding of dual AV nodal pathway physiology 
(with or without echo complexes) during electrophysiolog- 
ical study in patients in whom AVNRT is not .~uspected 
clinically 
Radiofrequency Catheter Ablation of Atrial Tachycardia, 
Flutter, and Fibrillation 
Atrial tachycardia nd atrial flutter were reported to- 
gether in the NASPE survey~3Z; the success rate was 75% in 
371 patients with a complication rate of 0.81% and no 
reported eaths. There are increasing numbers of publica- 
tions related to ablation of atrial tachycardias, 132,~37,143-15° 
including tachycardia n the region of the sinus node and 
ablation of inappropriate sinus tachycardiaA 47 Radiofre- 
quency ablation has also been effective in eliminating 
common atrial flutter. 143,~49 Although surgical procedures 
involving incision and isolation of atrial myocardium have 
been devised to eliminate atrial fibrillation and their feasi- 
bility has been demonstrated, catheter ablation techniques 
for eliminating atrial fibrillation are at a relatively early 
stage of development, but preliminary success has been 
reported. 151.152 
Recomendations for Radiofrequency Catheter Ablation of 
Atrial Tachycardia, Flutter, and Fibrillation 
Class I 
(1) Patients with atrial tachycardia that is drug resistant 
or the patient is drug intolerant or does not des,~re long- 
term drug therapy 
(2) Patients with atrial flutter that is drug resistant or 
the patient is drug intolerant or does not desire long-term 
drug therapy 153 
Class II 
(1) Atrial flutter/atrial tachycardia associated with par- 
oxysmal atrial fibrillation when the tachycardia is drug 
resistant or the patient is drug intolerant or does not desire 
long-term drug therapy 
(2) Patients with atrial fibrillation and evidence of a 
localized site(s) of origin when the tachycardia is drug 
resistant or the patient is drug intolerant or does not desire 
long-term drug therapy 
Class I l l  
(1) Patients with atrial arrhythmia that is responsive to 
drug therapy, well tolerated, and preferred by the patient o 
ablation 
(2) Patients with multiform atrial tachycardia 
Radiofrequency Catheter Ablation of Accessory Pathways 
The safety, efficacy 132,137,154-160 and cost-effectiveness ~6~ 
of radiofrequency ablation of an accessory AV pathway has 
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made ablation the treatment of choice in most patients who 
have AV reentrant aehycardia or atrial fibrillation (or 
other atrial tachyarrhythmias) sociated with a rapid ven- 
trieular esponse via the accessory pathway. Results from 
the literature 13~,,':5,137,154-161 and the NASPE survey 132 are 
comparable. The NASPE survey reports success rates of 
91% in 2527 left free-wall accessory pathways, 87% in 1279 
septal pathways, and 82% in 715 right free-wall pathways; 
overall rates of complications and death were 2.1% and 
0.2%, respectively. Complications include the possibility of 
valve damage, pericardial tamponade, AV block, and pulmo- 
nary or systemic emboli. Rare late deaths have been 
reported. 137 
Recommendations for Radiofrequency Catheter Ablation 
of Aect 'sory Pathways 
Class I 
(1) Patients with symptomatic AV ~eentrant tachycardia 
that is drug resistant or the patient is drug intolerant or 
does not desire long-term drug therapy 
(2) Patients with atrial fibrillation (or other atrial tachy- 
arrhythmia) nd a rapid ventricular response via the acces- 
sory pathway when the tachycardia s drug resistant or the 
patient is drug intolerant or does not desire long-term drug 
therapy 
Class H 
(1) Patients with AV reentrant tachycardia or atrial 
fibrillation with rapid ventricular ates identified during 
electrophysioiogical study of another arrhythmia 
(2) Asymptomatic patients with ventricular preexcita- 
tion whose livelihood or profession, important activities, 
insurability, or mental well being or the public safety would 
be affected by spontaneous tachyarrhythmias or the pres- 
ence of the ECG abnormality 
(3) Patients with atrial fibrillation and a controlled 
ventricular response via the accessory pathway 
(4) Patients with a family history of sudden cardiac 
death 
Class III 
Patients who have accessory pathway-related arrhyth- 
mias that are responsive to drug therapy, well tolerated, and 
preferred by the patient o ablation 
Radiofrequent~ Catheter Ablation of 
Ventricular Tachycardia 
Radiofrequency ablation of VT has been used with 
varying degrees of success in patients with ischemic dis- 
ease,~3z, ~62-~65 cardiomyopathy, ~32bundle branch reen- 
try, 166,167 and various forms of idiopathic VT. 5°.t68-~7° In the 
NASPE survey, ~a2 there was a successful ablation rate of 
71% overall in 429 patients with VT ; 85% in 224 patients 
with structurally normal hearts; 54% in 115 with ischemic 
heart disease; and 61% in 90 with idiopathic ardiomyop- 
athy. Complications occurred in 3%, with no reported 
deaths. Mapping and ablation techniques differ, depending 
on the type of VT. In patients without structural heart 
disease, only a single VT is usually present, and catheter 
ablation is curative. In patients with extensive structural 
heart disease, especially those with prior MI, multiple VTs 
are often present. Catheter ablation of a single VT ;,n such 
patients may be only palliative and may not eliminate the 
need for other antiarrhythmic therapy. 
Recommendations for Radiafrequency Catheter Ablation 
of Ventricular Tachycardia 
Class I 
(1) Patients with symptomatic sustained monomorphic 
VT when the tachycardia s drug resistant or the patieat is 
drug intolerant or does not desire long-term drug therapy 
(2) Patients with bundle branch reentrant ventricular 
tachycardia 
(3) Patients with sustained monomorphic VT and an 
ICD who are receiving multiple shocks not manageable by 
reprogramming or concomitant drug therapy 
Class II 
Nonsustained VT that is symptomatic when the tachy- 
cardia is drug resistant or the patient is drug intolerant or 
does not desire long-term drug therapy 
Class IH 
(i) Patients with VT that is responsive to drug, ICD, or 
svrgical therapy and that therapy is well tolc:-ated and 
preferred by the patient o ablation 
(2) Unstable, rapid, multiple, or polymorphic VT that 
cannot be adequately localized by current mapping 
techniques 
(3) Asymptomatic and clinically benign nonsustained VT 
XVI. Role of Electrophysiological Study in 
Pediatric Patients: Differences From Adults 
Although there are nuances pecific to pediatric pa- 
tients, performance and inteipretation of intracardiac 
electrophysiological studies in children are generally similar 
to those in adults. Indications for electrophysioiogicai stud- 
ies in children are also similar to general indicatious in 
adults. However, there are differences in some areas. The 
patient's age can influence indications for an electrophysi- 
ological study and dictate technical decisions, as can the 
presence of associated congenital heart lesions. 
Need for Sedation 
Small children, and even adolescents, have special re- 
quirements for sedation. The electrophysiological effects of 
sedation can be vagolytic (meperidine and promethazine) 
or sympathomimetic (ketamine). ~7u~7"- In a child, physiolog- 
ical conditions may change throughout a study with the 
addition of different types of sedation as well as different 
states of wakefulness. For this reason, tests of sinus node 
function and AV conduction as well as refractory periods of 
accessory connections may be less reproducible and poten- 
tially less valid in children than in adults. 
Prognostic Testing in "High-Risk" Groups 
Some children, such as those who have had repair of 
some types of congenital heart disease, are thought to be at 
high risk for arrhythmic death. 1~3-~75 No randomized studies 
have been carried out to determine if intervention alters 
568 Z|pES ET AL J'ACC Vol. 26, No. 2 
ACC/AHA TASK FORCE REPORT Augugt 1995:555-73 
outcome in such patients. Some pediatric ardiologists have 
advocated the use of electrophysiological studies to identify 
postsurgical patients who may be at higher risk for sudden 
deathJ 76 Although most ventricular ectopy in children with 
normal hearts is benign, nonsustained VT or premature 
ventricular complexes that are not suppressed with exercise 
may be the first sign of an otherwise subclinical myopathy 
or myocarditis. Some attthors have advocated electrophys- 
iological studies in these patients. 177 "llae risk of some 
a=hythmias may be greater in children than in adults 
because the adult population represents urvivors. The 
incidence of sudden death in children is low, so prospect:,ve 
data on this subject are limited? 7s 
Pediatric Tachycardias 
Incessant supraventricular tachycardias can lead to car- 
diomyopathy that occasionally is severe enough to require 
cardiac transplantation. 179The major causes are atrial 
automatic tachycardia nd the permanent form of junc- 
tional reciprocating tachycardia nd atypical AV node 
reentry. These conditions are relatively uncommon in 
adults but more common in children, and atrial automatic 
tachycardia can be confused with sinus tachycardia. In a 
child with dilated cardiomyopathy believed to have "sinus 
tachycardia," it may be important to perform electrophys- 
iological mapping to distinguish chronic atrial tachycardia 
from sinus tachycardia. Electrophysiological studies and 
mapping followed by ablation have resulted in return of 
normal cardiac function? s° Electrophysiological studies 
with radiofrequency atheter ablation have been very sue- 
cessful in treating each mechanism of supraventricular 
tachycardia in infants and children, with the exception of 
atrial fibrillation? s! The greatest number of ablations have 
been performed for reentry using an accessory connection 
and AV nodal reentry. 1s2 Certain VTs and atrial flutter in 
children may also be treated by ablation. While indications 
for ablation are generally similar in pediatric patients and 
adults, recent data from animals suggest hat the ablation 
lesion can enlarge in children as they grow. Therefore, until 
longer foil-w-up data are available, the long-term risk of 
ablation, particularly in younger children, is not well 
established. 
Complete .4trioventricular Block 
Congenital complete AV block most often occurs with a 
narrow QRS escape rhythm. Electrophysiological studies 
have not been demonstrated clinically useful in this situa- 
tion. However, if congenital complete AV block occurs with 
a wide QRS escape rhythm, such studies could provide data 
to determine the site of block and the presence of infran- 
odal disease. Acquired complete AV block in children is 
considered an indication for a permanent pacemaker, and 
electrophysiological studies are not necessary. Electrophys- 
ioiogical studies have not been benefcial in predicting 
prognosis in asymptomatic patients with surgically acquired 
bifascicular block. They may be useful in some post_,pera- 
rive patients with transient complete AV block. 
Recommendations for Electrophysiological Studies 
Class I 
(1) Pediatric patients with conditions or characteristics 
similar to those described in the sections on adults 
(2~ Patients with an undiagnosed narrow QRS 
tachycardia that cannot be distinguished from sinus 
tachycardia 
Class I I  
(1) Pediatric patients with conditions or characteristics 
similar to those described in the sections on adults 
(2) Asymptomatic patients possibly at high risk for 
sudden arrhythmic death, such as the postoperative patient 
with complex congenital heart disease or a normal heart 
with complex ventricular arrhythmias (nonsustained VT or 
premature ventricular complexes that fail to suppress dur- 
ing exercise) 
(3) Patients with congenital complete AV block and 
wide QRS escape rhythm 
Class m 
(1) Pediatric patients with conditions or characteristics 
similar to those described in the sections on adults 
(2) Patients with congenital complete AV block and 
narrow QRS escape rhythm 
(3) Patients with acquired complete AV block 
(4) Asymptomatic patients with surgically induced bifas- 
cicular block 
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